Orchard Therapeutics jumps on FDA nod for human trials of genetic disease therapy
05/01/2023 13:41
** Shares of gene therapy developer Orchard Therapeutics Plc
ORTX.O rise 61% to ~83 cents premarket
** Co says U.S. FDA allows human trials for its experimental
gene therapy to treat a form of genetic neurometabolic disease
called mucopolysaccharidosis type I (MPS-I)
** MPS-I is caused by the deficiency of an enzyme which is
required to break down sugar molecules called glycosaminoglycans
** Co plans to begin trial evaluating safety and efficacy of
OTL-203 compared to standard-of-care in H2 this year
** Shares of ORTX fell 71.9% last year
(Reporting by Mariam E Sunny)
((Mariam.ESunny@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln